Search

Long-Acting HIV Treatment Pipeline

AVAC has begun to track the research pipeline for long-acting HIV treatment (LA-ART). A rapidly expanding pipeline for LA-ART has the potential to introduce new regimens with dosing frequencies that range from weeks to months to, eventually, years. The benefits of LA-ART include reduced drug dosing, frequency, and number of drugs, with the potential for associated decreases in the cost of medications and the burden on health systems. New drug classes could close treatment gaps in children, adolescents, and those with high viremia, comorbidities and resistance.

PxWire Volume 16, Issue 2

This issue showcases AVAC’s analysis of the recent PEPFAR data release, assessing how uptake of prevention programs—particularly PrEP initiations—have declined over the last year. As the field grapples with the lasting impact of the US government’s cuts to PEPFAR programs, AVAC takes a closer look at what the data show and what is still missing.

Inside the Decisions that Changed Global Health

Join us Wednesday, May 20 at 10am ET for a conversation with Nicholas Enrich, author of Into the Wood Chipper and former global health lead at USAID. This webinar will provide Enrich’s inside perspective on the decisions that led to the dismantling of USAID and the foreign aid freeze and what they mean for global health today.

Inside the Decisions that Changed Global Health: An AVAC Conversation with Nicholas Enrich

CROI Cure Reflections Video Series

Produced by PAVE (Pediatric Adolescent Virus Elimination), this weekly series of four videos provides HIV cure-related takeaways from CROI 2026.

Global Health Watch: PEPFAR Data, Latest in Health Deals, Lawmakers Oppose Redirected Global Health Funding, Pushback on Expanded Gag Rule

On the heels of the recent PEPFAR data release, a New York Times article this week serves as an illustration of the consequences of the US policy decisions on lives. It shows what the policy shifts, funding disruptions, and data gaps covered in this issue, look like in Zambia: strained clinics, interrupted HIV services, and uncertainty for patients and providers relying on PEPFAR.

Accelerating the Health Equity Impact of Interventions for Infectious Diseases in Africa

Attending INTEREST 2026? Resources to Support Your Participation

INTEREST will take place 12-15 May in Tanzania, covering new advances in HIV prevention, treatment, cure, and vaccine R&D; implementation science; and how science is being translated into impact. AVAC has compiled resources and highlights.

Uganda Key Populations Consortium Conversation on LEN

AVAC Infographics for INTEREST 2026

For those presenting at INTEREST, AVAC’s latest infographics on HIV R&D and the delivery pipeline, the current landscape of prevention options are available in an easy-to-use slide format—including lenacapavir for HIV PrEP volume commitments, and the impact of US funding cuts with new data from PEPFAR.